Elixirgen Therapeutics, Inc. is a clinical-stage biotechnology company focused on the treatment of rare and aging-associated diseases. One of our lead products, EXG34217, a cell-based gene therapy, is currently being investigated in a Phase I/II, open label study in patients with telomere biology disorders with bone marrow failure, such as dyskeratosis congenita.
Currently, Elixirgen does not offer an expanded access program for EXG34217. Given the current stage of our development program, we believe that participation in our clinical trial is the most appropriate way to access this investigational therapy. We believe that access to EXG34217 should be limited to controlled clinical trials until such time as its safety and efficacy have been determined and confirmed by regulatory authorities.
Consistent with the 21st Century Cures Act, Elixirgen may revise this policy at any time.
Last updated: February 2025